🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 49 of 55

  1. Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  2. Tunlametinib+PD-1 mAb

    BEONE MEDICINES AUS PTY LTD

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  3. Tuspetinib

    Aptose Biosciences

    Leukemia, Myeloid, Acute

    phase 2 small molecule active

    1 trial

  4. US-guided RFA

    The First People's Hospital of Lianyungang

    Liver Cancer

    phase 2 other active

    1 trial

  5. US-guided laser ablation for refractory neoplasms

    The First People's Hospital of Lianyungang

    Refractory Neoplasms

    phase 2 other active

    1 trial

  6. Ubamatamab

    Regeneron UK Limited

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  7. Ubamatamab

    Regeneron UK Limited

    Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  8. Ubamatamab

    Regeneron UK Limited

    Advanced/Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Ubamatamab, TOCILIZUMAB, Ubamatamab, Kevzara 175 mg/ml solution for injection, CEMIPLIMAB, LIBTAYO 350 mg concentrate for solution for infusion., Sarilumab

    Lacuna Pharma Pty Ltd

    Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  10. Ublituximab

    TG THERAPEUTICS, INC.

    Non-Hodgkins Lymphoma

    phase 2 small molecule completed

    2 trials

  11. Ublituximab

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  12. Umbralisib

    TG THERAPEUTICS, INC.

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  13. Umbralisib

    TG THERAPEUTICS, INC.

    Marginal Zone Lymphoma

    phase 2 small molecule completed

    1 trial

  14. Umbralisib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    4 trials

  15. Utidelone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 small molecule active

    1 trial

  16. VACl

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule active

    1 trial

  17. VATS

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other active

    1 trial

  18. VCAR33

    Vor Biopharma

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

  19. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Kaposi's Sarcoma

    phase 2 small molecule terminated

    1 trial

  20. VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, DOXORUBICIN HYDROCHLORIDE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Primary plasma cell leukemia

    phase 2 small molecule active

    1 trial

  21. VEN (Venetoclax)

    The First People's Hospital of Lianyungang

    Myelodysplastic Neoplasms

    phase 2 small molecule active

    1 trial

  22. VEN (Venetoclax)

    The First People's Hospital of Lianyungang

    Adult T-cell Leukemia/Lymphoma

    phase 2 small molecule active

    1 trial

  23. VENETOCLAX , Epcoritamab, Epcoritamab, VINCRISTINE , Jaypirca 100 mg film-coated tablets, DOXORUBICIN , Jaypirca 50 mg film-coated tablets, CYCLOPHOSPHAMIDE , PREDNISOLONE , LENALIDOMIDE , RITUXIMAB

    Genmab A/S

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  24. VENETOCLAX, VENETOCLAX, SY-1425, VENETOCLAX, AZACITIDINE

    Lacuna Pharma Pty Ltd

    RARA-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  25. VENETOCLAX, VENETOCLAX, VENETOCLAX, AZACITIDINE

    Fondazione Telethon ETS

    Acute Myeloid Leukemia with NPM1 mutation

    phase 2 small molecule active

    1 trial

  26. VESANOID 10 mg, capsule molle

    The George Institute

    Oligometastatic solid cancer

    phase 2 small molecule active

    1 trial

  27. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Anal Neoplasm

    phase 2 mab completed

    1 trial

  28. VINCRISTINE , MELPHALAN , DOXORUBICIN , CYCLOPHOSPHAMIDE , IFOSFAMIDE , Trecondi 1 g powder for solution for infusion, ETOPOSIDE , Trecondi 5 g powder for solution for infusion

    Fondazione Telethon ETS

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  29. VINORELBINE , GEMCITABINE, BENDAMUSTINE , ATEZOLIZUMAB , VINORELBINE TARTRATE, GEMCITABINE , BENDAMUSTINE HYDROCHLORIDE

    Fondazione Telethon ETS

    Hodgkin’s lymphoma

    phase 2 small molecule active

    1 trial

  30. VIR-5818

    Vir Biotechnology

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 small molecule active

    1 trial

  31. VK-2019

    Cullinan Therapeutics

    Nasopharyngeal Carcinoma

    phase 2 small molecule terminated

    1 trial

  32. VOR33

    Vor Biopharma

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

  33. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 small molecule active

    1 trial

  34. VV1

    Regeneron UK Limited

    Melanoma

    phase 2 mab active

    1 trial

  35. VX15/2503 + avelumab

    VACCINEX, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  36. Vaccine

    Atrium Therapeutics

    Pediatric Cancer

    phase 2 mab active

    1 trial

  37. Valemetostat Tosylate, Golcadomide, RITUXIMAB, Valemetostat Tosylate, Golcadomide, RITUXIMAB, Golcadomide

    Celgene Europe Limited

    Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  38. Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  39. Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    Relapsed/Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  40. Valemetostat Tosylate, Valemetostat Tosylate

    The George Institute

    Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.

    phase 2 small molecule active

    1 trial

  41. Varnimcabtagene autoleucel, BENDAMUSTINE, FLUDARABINE, DEXCHLORPHENIRAMINE, CYCLOPHOSPHAMIDE, PARACETAMOL, TOCILIZUMAB, ALLOPURINOL

    The George Institute

    Acute lymphoid leukemia

    phase 2 small molecule active

    1 trial

  42. Vebreltinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Potentially Resectable MET-altered Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  43. Vectibix 20 mg/ml concentrate for solution for infusion, VALPROIC ACID, VALPROIC ACID, Irinotecan Accord 20 mg/ml concentrato per soluzione perinfusione

    Fondazione Telethon ETS

    RAS/BRAF wild-type metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  44. Venclyxto 100 mg film-coated tablets, Azacitidine Kabi 25 mg/mL powder for suspension for injection

    The George Institute

    acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  45. Venclyxto 100 mg film-coated tablets, RITUXIMAB, Calquence 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, RITUXIMAB, Venclyxto 10 mg film-coated tablets

    AstraZeneca AB

    Treatment Naïve Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  46. Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets

    AstraZeneca AB

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    phase 2 small molecule active

    1 trial

  47. Venclyxto 50 mg film-coated tablets, JNJ-54179060, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, IMBRUVICA 140 mg hard capsules

    Janssen-Cilag International N.V.

    Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  48. Venetoclax

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.